2022-05-12T07:54:35-05:00 2021-06-30 135565207 KPMG LLP 90 S 7TH STREET STE 4200 MINNEAPOLIS MN 55402 990 2020-07-01 954335088 LYMPHOMA RESEARCH FOUNDATION LYMP 2123492910 WALL ST PLAZA 88 PINE STREET NEW YORK NY 10005 MEGHAN GUTIERREZ CEO 2123492910 2022-05-10 1 MEGHAN GUTIERREZ 999009999 HOLLY K MOEN P01800653 6123055000 2022-04-29 0 AAL1 IAL1 2020 2022-09-23 18:48:47Z MEGHAN GUTIERREZ WALL ST PLAZA 88 PINE STE 240 NEW YORK NY 10005 16350037 0 X WWW.LYMPHOMA.ORG X 2001 NY TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. FOR MORE INFORMATION, SEE SCHEDULE O. 17 17 34 20000 0 0 9778478 10361473 3922980 5533517 313409 231486 -69915 -22618 13944952 16103858 1069898 2240100 0 0 3204493 3026792 0 0 1531091 3897002 2869739 8171393 8136631 5773559 7967227 22709643 31207101 3997100 4587960 18712543 26619141 X THE LYMPHOMA RESEARCH FOUNDATION'S (LRF) MISSION IS TO ERADICATE LYMPHOMA AND SERVE THOSE TOUCHED BY THIS DISEASE. SEE SCHEDULE O.LRF IS DEDICATED TO IDENTIFYING A CURE THROUGH AN INNOVATIVE RESEARCH PROGRAM AND TO HELPING MEMBERS OF THE LYMPHOMA COMMUNITY BY PROVIDING COMPREHENSIVE, DISEASE-SPECIFIC PROGRAMS AND SUPPORT SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSISTTHOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 20,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLICCOMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK. BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. 0 0 2895846 2202500 39700 RESEARCH: THE FOUNDATION IS COMMITTED TO FUNDING THE MOSTPROMISING LYMPHOMA RESEARCHERS WHO HAVE THE GREATEST POTENTIAL TOADVANCE PATIENT CARE AND IMPROVE PATIENT OUTCOMES. THROUGH ITSLYMPHOMA CONSORTIA, RESEARCH INITIATIVES, AND SCIENTIFICWORKSHOPS, LRF MOBILIZES THE RESEARCH COMMUNITY TO SPEED THEDEVELOPMENT AND USE OF NEW TREATMENTS. SEE SCHEDULE O. 1761770 37600 5533517 EDUCATIONAL PROGRAMS AND PATIENT SERVICES: LRF PROVIDES ACOMPREHENSIVE SERIES OF PROGRAMS AND SERVICES FOR THE LYMPHOMACOMMUNITY INCLUDING, BUT NOT LIMITED TO, CONTINUING MEDICALEDUCATION, CLINICAL TRIALS INFORMATION SERVICES, DISEASE SPECIFICPUBLICATIONS AND WEBSITES, IN-PERSON PATIENT WORKSHOPS ANDEDUCATIONAL FORUMS, LYMPHOMA HELPLINE, ONLINE SERVICES, PATIENTAID GRANTS, TELECONFERENCES AND WEBCASTS/PODCASTS, WITH AVOLUNTEER COMMUNITY NETWORK. 1121233 COMMUNICATION AND ADVOCACY: THROUGH STRATEGIC COMMUNICATIONS, LRF SEEKS TO RAISE AWARENESS OF LYMPHOMA AND THE NEEDS OF PEOPLE WITH LYMPHOMA. DIGITAL PROGRAMMING ENSURES ACCESS TO ACCURATE INFORMATION AND DIGITAL PROGRAMS INCLUDING MOBILE APPS. LRF'S ADVOCACY PROGRAM ENABLES VOLUNTEERS TO REPRESENT THE NEEDS OF PEOPLE WITH LYMPHOMA BY SUPPORTING PUBLIC POLICIES WHICH SEEK TO INCREASE FEDERAL FUNDING FOR LYMPHOMA RESEARCH AND ENSURE ACCESS TO HIGH QUALITY CANCER CARE. 5778849 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 1 0 0 0 0 0 1 0 0 1 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 33 0 1 34 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 17 17 0 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 0 1 1 AL AR CA FL GA HI IL KS KY MD MA MI MN MS MO NV NH NJ NM NY NC OR PA RI SC TN UT VA WV WI X X CAROL FLORES 2123492910 WALL ST PLAZA 88 PINE STE 2400 NEW YORK NY 10005 MICHAEL WERNER IMMEDIATE PAST CHAIR 1.00 0.00 X 0 0 0 SHERI ROSENFELD BOARD MEMBER (END 7/1/20) 1.00 0.00 X 0 0 0 STEVEN J PRINCE PAST CHAIR 1.00 0.00 X 0 0 0 SCOTT PANSKY BOARD MEMBER (BEG 7/1/20) 1.00 0.00 X 0 0 0 JOHN A NELSON BOARD MEMBER 1.00 0.00 X 0 0 0 ROBERT MCAULEY BOARD MEMBER 1.00 0.00 X 0 0 0 JOHN LEONARD MD PAST CHAIR, SAB 1.00 0.00 X 0 0 0 KEITH HOOGLAND BOARD MEMBER 1.00 0.00 X 0 0 0 THOMAS E GOLDSTONE BOARD MEMBER 1.00 0.00 X 0 0 0 MICHAEL FROY BOARD MEMBER 1.00 0.00 X 0 0 0 KEVIN FENNESSEY BOARD MEMBER 1.00 0.00 X 0 0 0 TOM CONDON BOARD MEMBER (END 7/1/20) 1.00 0.00 X 0 0 0 DR MORTON COLEMAN BOARD MEMBER - CHAIR MAB 1.00 0.00 X 0 0 0 ERIC COHEN BOARD MEMBER (END 7/1/20) 0.00 0.00 X 0 0 0 MICHAEL AKINYELE BOARD MEMBER 1.00 0.00 X 0 0 0 LEIGH OLSON SECRETARY 2.00 0.00 X X 0 0 0 KIM METCALF VICE CHAIR 2.00 0.00 X 0 0 0 JEFF BLOCK VICE CHAIR AND TREASURER 2.00 0.00 X X 0 0 0 STEVEN EICHBERG BOARD CHAIR 5.00 0.00 X X 0 0 0 ANDREW ZELENETZ CHAIR, SAB 1.00 0.00 X 0 0 0 BRUCE YABLON BOARD MEMBER (END 7/1/20) 1.00 0.00 X 0 0 0 MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 35.00 0.00 X 264381 0 13989 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 35.00 0.00 X 148113 0 49783 KINYA HARTE DIRECTOR OF COMM. & MARKETING 35.00 0.00 X 103822 0 19700 GARY JAWORSKI CHIEF DEVELOPMENT OFFICER 35.00 0.00 X 127499 0 15460 SARAH QUINLAN SR DIRECTOR OF PROGRAM 35.00 0.00 X 146996 0 12968 790811 0 111900 5 0 1 0 BUILD CONSULTING LLC 1101 14TH STREET SUITE 830 WASHINGTON DC 20005 IT CONSULTING 231771 BLACKBAUD INC 2000 DANIEL DRIVE CHARLESTON SC 29492 SYSTEM MAINTENANCE 157946 MUNROE DESIGN GROUP INC 121 SOUTH BROAD STREET SUITE 1900 PHILADELPHIA PA 19107 PRINTING AND DESIGN 116907 GRAVITY JACK INC 157 S HOWARD ST SUITE 605 SPOKANE WA 99201 CONSULTING 116655 J SQUARED PRESS INC DBA J2PRESS PO BOX 158 ORANGEBURG NY 10962 PRINTING AND PUBLICA 104274 5 18279 2136943 8206251 134146 10361473 EDUCATION PROGRAMS & PATIENT SERV 812900 5533517 5533517 5533517 234178 234178 131454 134146 -2692 -2692 -2692 49715 2136943 112033 -62318 -62318 OTHER ACTIVITIES 900099 39700 39700 39700 16103858 5573217 0 169168 X 2192500 2192500 37600 37600 10000 10000 545081 298361 93452 153268 1855984 1030041 296810 529133 62397 36454 7216 18727 305813 117027 128669 60117 257517 142918 41182 73417 25371 13512 4918 6941 71025 71025 30000 30000 834475 564749 46395 223331 438683 405550 1647 31486 179669 155021 9554 15094 66931 50570 5877 10484 394388 218879 63071 112438 42694 38379 593 3722 279221 179019 4066 96136 57728 32038 9232 16458 30395 16869 4861 8665 MISCELLANEOUS & OTHER E 276823 162305 27571 86947 PROCESSING FEES & OTHER 106028 26978 4766 74284 REPAIRS AND MAINTENANCE 23891 13259 3821 6811 LICENSES AND PERMITS 12417 6820 1965 3632 8136631 5778849 826691 1531091 3166522 5490247 17629218 20746346 100000 973670 4579682 222328 235074 371962 216814 192146 155148 425759 604 22709643 31207101 600502 623001 2614298 3199409 782300 279250 486300 3997100 4587960 X 4684499 5562400 14028044 21056741 18712543 26619141 22709643 31207101 X 7967227 -170804 110175 0 X 0 1 X 1 0 X 7784192 7229093 7623538 9778478 10361473 42776774 7784192 7229093 7623538 9778478 10361473 42776774 8957091 33819683 95465 116297 227921 312354 234178 986215 18492 15189 14788 2356 39700 90525 43853514 19059530 0.77120 0.65960 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 1 0 0 0 0 1 30000 0 1 110847 140847 0 SCHEDULE C, PART II-B, LINE 1 OTHER LOBBYING ACTIVITIES: CONTACT WITH LEGISLATORS, THEIR STAFF, GOVERNMENT OFFICIALS, LEGISLATIVE BODIES, AND ASSOCIATED GRASSROOTS ACTIVITIES TO PRESENT ISSUES OF CONCERN RELATED TO LYMPHOMA. 113640 47829 65811 254786 166510 88276 3536 2475 1061 155148 X 17169057 -170804 1123970 953166 16215891 -112033 -112033 16103858 9262459 1123970 -110175 112033 1125828 8136631 0 8136631 PART X, LINE 2: THE FOUNDATION RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT OF BEING SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO THE FOUNDATION'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THE FOUNDATION DID NOT RECOGNIZE ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEAR ENDED JUNE 30, 2021 OR 2020. PART XI, LINE 4B - OTHER ADJUSTMENTS: FUNDRAISING EXPENSES -112,033. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EXPENSE 112,033. SCHEDULE D, PART XI & XII, LINE 4B & 2D EXPENSES RELATED TO FUNDRAISING EVENTS ARE REPORTED IN PART VIII, STATEMENT OF REVENUE, LINE 8B, TOGETHER WITH FUNDRAISING EVENTS REVENUE. 1 0 0 0 0 0 0 0 0 0 NORTH AMERICA MENTORING 10000 CHECK CASH 1 0 0 0 0 0 0 PART III ACCOUNTING METHOD: AL AR CA FL GA HI IL KS KY MD MA MI MN MS MO NV NH NJ NM NY NC OR PA RI SC TN UT VA WV WI TEAM LRF 831223 831223 20680 3555 30 ANNUAL GALA 769360 769360 1111 3750 124 2 586075 536360 49715 21958 59675 1150 2186658 2136943 49715 43749 63230 4900 154 112033 -62318 1 UNIVERSITY OF PENNSYLVANIA 3400 CIVIC CENTER BLVD PCAM SPE 8-112 PHILADELPHIA PA 19104 231352685 501(C)(3) 225000 CASH CAREER DEVELOPMENT AWARD DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 225000 CASH CAREER DEVELOPMENT AWARD EMORY UNIVERSITY - WINSHIP CANCER INSTITUTE 1365 CLIFTON RD NE BUILDING B 4011 ATLANTA GA 30322 580566256 501(C)(3) 225000 CASH CAREER DEVELOPMENT AWARD ST JUDE CHILDREN'S RESEARCH HOSPITAL INC 262 DANNY THOMAS PLACE 260 MEMPHIS TN 381050367 620646062 501(C)(3) 225000 CASH CAREER DEVELOPMENT AWARD DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE MA513 BOSTON MA 02115 042263040 501(C)(3) 105000 CASH FELLOWSHIP AWARD UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL OFFICE OF SPONSORED RESEARCH 104 AIRPORT DRIVE SU CHAPEL HILL NC 275991350 566001393 501(C)(3) 105000 CASH FELLOWSHIP AWARD WEILL CORNELL MEDICAL COLLEGE 413 E 69TH ST MELNICK LAB BELFER RESEARCH BUILDIN NEW YORK NY 10021 131623978 CORPORATION 105000 CASH FELLOWSHIP AWARD FRED HUTCHINSON CANCER RESEARCH CENTER OFFICE OF SPONSORED RESEARCH 1100 FAIRVIEW AVENUE SEATTLE WA 981091024 999999999 OPEN 105000 CASH FELLOWSHIP AWARD BRIGHAM AND WOMEN'S HOSPITAL HARVARD MEDICAL SCHOOL 181 LONGWOOD AVE RM 857 BOSTON MA 02115 042312909 501(C)(3) 105000 CASH FELLOWSHIP AWARD DANA-FARBER CANCER INSTITUTE 450 BROOKLINE PLACE D512 BOSTON MA 02115 042263040 501(C)(3) 105000 CASH FELLOWSHIP AWARD NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE SMILOW 1303 NEW YORK NY 10016 999999999 OPEN 105000 CASH FELLOWSHIP AWARD REGENTS OF THE UNIVERSITY OF MINNESOTA - TWIN CITIES 1988 FITCH AVENUE SAINT PAUL MN 55108 416007513 GOVERNMENT 105000 CASH FELLOWSHIP AWARD PERELMAN SCHOOL OF MEDICINE UNIVERSITY OF PENNSYLVANIA STELLAR-CHANCE 422 CURIE BLVD PHILADELPHIA PA 191046100 231352685 501(C)(3) 105000 CASH FELLOWSHIP AWARD DANA-FARBER CANCER INSTITUTE (DFCI) BOSTON MA 450 BROOKLINE PLACE BOSTON MA 02115 042263040 501(C)(3) 105000 CASH FELLOWSHIP AWARD DARTMOUTH COLLEGE 1 MEDICAL CENTER DRIVE WRTB LEBANON NH 037561000 020222111 501(C)(3) 105000 CASH FELLOWSHIP AWARD JOAN & SANFORD I WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY 1300 YORK AVENUE SUITE C640A NEW YORK NY 10065 131623978 CORPORATION 20000 CASH MENTORING STANFORD UNIVERSITY SCHOOL OF MEDICINE LOKEY BUILDING ROOM G2115 265 CAMPUS DRIVE 5458 STANFORD CA 94305 941156365 OPEN 10000 CASH MENTORING MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 10000 CASH MENTORING MEMORIAL SLOAN KETTERING CANCER CENTER 530 E 74TH ST FLOOR 9 BOX 137 NEW YORK NY 10021 131924236 501(C)(3) 10000 CASH MENTORING ROSWELL PARK CANCER INSTITUTE ELM AND CARLTON STREETS BUFFALO NY 14263 161552370 PUBLIC BENEFIT 10000 CASH MENTORING EMORY UNIVERSITY - WINSHIP CANCER INSTITUTE 1365C CLIFTON ROAD NE SUITE C2001 ATLANTA GA 30322 580566256 501(C)(3) 10000 CASH MENTORING WEILL CORNELL MEDICAL COLLEGE 525 E 70TH ST STARR 341 NEW YORK NY 10065 131623978 CORPORATION 10000 CASH MENTORING UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 STATE AGENCY 10000 CASH MENTORING MAYO CLINIC 200 1ST STREET SW ROCHESTER MN 55905 999999999 OPEN 10000 CASH MENTORING SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 10000 CASH MENTORING MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT ST YAWKEY 9E BOSTON MA 021142696 042697983 501(C)(3) 10000 CASH MENTORING THE OHIO STATE UNIVERSITY COMPREHENSIVE CANCER CENTER 320 W 10TH AVE A34 COLUMBUS OH 432101267 316025986 GOVERNMENT 10000 CASH MENTORING 11 10 PATIENT AID GRANTS 376 37600 CASH PATIENT AID GRANTS SCHEDULE I, PART I, LINE 2 LRF'S EXPERT SCIENTIFIC ADVISORY BOARD (SAB) CONDUCTS PEER REVIEW FOR ALL GRANT PROPOSALS AND RECOMMENDS THE HIGHEST-SCORING PROPOSALS TO THE LRF BOARD OF DIRECTORS FOR FUNDING. THE BOARD OF DIRECTORS THEN CONSIDERS AND APPROVES THE GRANTS WHICH ARE TO BE FUNDED. ONCE A GRANT IS APPROVED AND ACCEPTED BY THE GRANTEE, THE GRANTEE WILL BEGIN TO RECEIVE INSTALLMENTS BASED UPON THE PAYMENT SCHEDULE AS DICTATED IN THE GRANT CONTRACT. THE SAB AND LRF'S RESEARCH DEPARTMENT ANNUALLY REVIEW EACH GRANTEE'S PROGRESS AGAINST DELIVERABLES AND APPROVES THE CONTINUATION OF GRANT PAYMENTS. SCHEDULE I, PART III LRF PROVIDES FINANCIAL ASSISTANCE TO LYMPHOMA PATIENTS WHO STRUGGLE TO PAY FOR EXPENSES RELATED TO THEIR LYMPHOMA TREATMENTS, SUCH AS MEDICAL BILLS AND TRANSPORTATION COSTS. LRF SUPPORT SERVICES STAFF REVIEWS THE APPLICATIONS, VALIDATES APPLICATION CRITERIA AND SUBMITS APPLICATIONS FOR PAYMENT APPROVAL TO DEPARTMENT LEADERSHIP. X X X 1 0 0 0 0 0 0 0 0 MEGHAN GUTIERREZ CHIEF EXECUTIVE OFFICER 264381 0 0 0 0 0 13250 0 739 0 278370 0 0 0 CAROLINA FLORES SENIOR DIRECTOR OF FINANCE 148113 0 0 0 0 0 8109 0 41674 0 197896 0 0 0 SARAH QUINLAN SR DIRECTOR OF PROGRAM 146996 0 0 0 0 0 0 0 12968 0 159964 0 0 0 PART I, LINE 4A GARY JAWORSKI, CHIEF DEVELOPMENT OFFICER, RECEIVED SEVERANCE PAYMENT IN CALENDAR YEAR 2020 FOR THE AMOUNT OF $13,168. X 18 134146 FMV 0 1 0 FORM 990, PART I, LINE 1 AND PART III, LINE 1 LRF IS THE NATION'S LARGEST NON-PROFIT ORGANIZATION DEVOTED EXCLUSIVELY TO FUNDING INNOVATIVE RESEARCH AND SERVING THE LYMPHOMA COMMUNITY THROUGH A COMPREHENSIVE SERIES OF EDUCATION PROGRAMS, OUTREACH INITIATIVES, AND PATIENT SERVICES. LRF INVESTS MILLIONS OF DOLLARS EVERY YEAR TO COMBAT LYMPHOMA AND ASSIST THOSE WHOSE LIVES HAVE BEEN AFFECTED BY A LYMPHOMA DIAGNOSIS. LRF IS SUPPORTED BY MORE THAN 20,000 VOLUNTEERS WHO CONTRIBUTE THEIR TIME AND TALENTS TO FURTHER THE LRF MISSION AND SERVE THEIR LOCAL COMMUNITIES. LRF HAS EARNED THE TRUST OF INDIVIDUALS, PRIVATE FOUNDATIONS, PUBLIC COMPANIES, AND ORGANIZATIONS THAT FUND ITS WORK BY DEMONSTRATING A HISTORY OF CAREFUL AND PROVEN FINANCIAL STEWARDSHIP. FORM 990, PART III, LINE 4A RESEARCH: LRF'S RESEARCH PROGRAM IS GUIDED BY THE LRF SCIENTIFIC ADVISORY BOARD (SAB), COMPRISED OF 45 OF THE WORLD'S LEADING EXPERTS IN LYMPHOMA RESEARCH AND PATIENT CARE. LRF FACILITATES NUMEROUS DISEASE-SPECIFIC GLOBAL CONSORTIA (INCLUDING PROGRAMS FOR FOLLICULAR, MARGINAL ZONE, MANTLE CELL AND ADOLESCENT AND YOUNG ADULT LYMPHOMAS) AND DEVELOPS SCIENTIFIC MEETINGS (INCLUDING WORKSHOPS ADDRESSING NEW LYMPHOMA AND CLL THERAPIES AND CLINICAL TRIALS) ANNUALLY, CONVENING INTERNATIONAL EXPERTS TO SHARE RESEARCH FINDINGS AND COLLABORATE, WITH A GOAL OF ADVANCING THE MOST PROMISING LYMPHOMA AND CLL RESEARCH. LRF FUNDS RELEVANT SENIOR INVESTIGATOR RESEARCH GRANTS AS WELL, SEEKING TO DEVELOP NEW TREATMENTS FOR LYMPHOMA. TO ENSURE THAT THE NEXT GENERATION OF CANCER RESEARCHERS ARE DEDICATED TO STUDYING LYMPHOMA, THE FOUNDATION IS COMMITTED TO INVESTING IN EARLY CAREER SCIENTISTS WHO HAVE THE GREATEST ABILITY TO IMPACT THE FUTURE OF LYMPHOMA RESEARCH. THE FOUNDATION'S EARLY CAREER INVESTIGATOR GRANT PORTFOLIO INCLUDES THE LRF CLINICAL CAREER DEVELOPMENT AWARD, LYMPHOMA SCIENTIFIC RESEARCH MENTORING PROGRAM, AND LRF POSTDOCTORAL FELLOWSHIP. FORM 990, PART VI, SECTION B, LINE 11B THE ORGANIZATION'S FORM 990 IS PREPARED INTERNALLY BY THE FINANCE DEPARTMENT AND IS REVIEWED BY MANAGEMENT BEFORE REVIEW BY THE ORGANIZATION'S INDEPENDENT ACCOUNTING FIRM. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE AND THE BOARD FOR COMMENT. FORM 990, PART VI, SECTION B, LINE 12C LRF HAS A CONFLICT OF INTEREST POLICY WHICH REQUIRES BOARD MEMBERS, OFFICERS, AND STAFF, TO REVIEW AND SIGN ANNUALLY. DURING THE FY 2021 FINANCIAL AUDIT, LRF'S EXTERNAL AUDITORS REVIEWED THE BOARD AND OFFICERS' STATEMENTS. NO CONFLICTS OF INTERESTS WERE REPORTED FOR THE FISCAL PERIOD ENDING JUNE 30, 2021. IN 2014, LRF ESTABLISHED A FORMAL PROCESS FOR REVIEW AND DISPOSITION OF POTENTIAL CONFLICTS OF INTEREST IN ACCORDANCE WITH THE PROVISIONS OF THE NEW YORK NON-PROFIT REVITALIZATION ACT OF 2013. FORM 990, PART VI, SECTION B, LINE 15A THE ORGANIZATION SETS COMPENSATION IN A MANNER GIVING RISE TO A REBUTTABLE PRESUMPTION THAT THE COMPENSATION IS REASONABLE UNDER STANDARDS SET FORTH IN TREASURY REGULATIONS SECTION 53.4958-6. SALARIES OF THE SENIOR STAFF, INCLUDING THE CEO, ARE DETERMINED BASED UPON MARKET INFORMATION COMPARABLE TO THE POSITION IN OTHER NON-PROFIT ORGANIZATIONS. THE CEO'S COMPENSATION IS APPROVED BY THE EXECUTIVE COMMITTEE (EC), WHICH HAS BEEN DULY AUTHORIZED BY THE BOARD AND CONSISTS OF INDEPENDENT MEMBERS, AND THE APPROVAL IS DOCUMENTED CONTEMPORANEOUSLY IN THE EC MINUTES. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE ON THE ORGANIZATION'S WEBSITE FOR PUBLIC VIEWING. SIGNED CONFLICT OF INTERESTS FORMS AND GOVERNING DOCUMENTS ARE KEPT ON FILE IN LRF'S MAIN OFFICE AND AVAILABLE FOR VIEW ON-SITE. FORM 990, PART IX, LINE 11G PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 564,749. MANAGEMENT AND GENERAL EXPENSES 46,395. FUNDRAISING EXPENSES 223,331. TOTAL EXPENSES 834,475. FORM 990, PART XI, LINE 8 REFUNDS/UNEXPENDED FUNDS FROM THE PRIOR YEARS GRANTS $110,175 LRF RESEARCH INC WALL STREET PLAZA/88 PINE ST STE 24 NEW YORK NY 10005 611844536 INVESTMENT NY LYMPHOMA RESEARCH FOUNDATION C 1.00000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0